甲基 5-醛基-1H-吡咯-2-甲酸酯 | 1197-13-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 甲基 5-醛基-1H-吡咯-2-甲酸酯
• 中文别名: 5-甲酰基-1H-吡咯-2-羧酸甲酯；甲基5-醛基-1H-吡咯-2-甲酸酯
• 英文名称: methyl 5-formyl-1H-pyrrole-2-carboxylate
• 英文别名: methyl 5-formylpyrrole-2-carboxylate
• CAS: 1197-13-3
• 化学式: C₇H₇NO₃
• mdl: MFCD09878545
• 分子量: 153.137
• InChiKey: PRCYHYGREGWAAN-UHFFFAOYSA-N

物化性质

• 熔点：
  96 °C
• 沸点：
  313.2±27.0 °C(Predicted)
• 密度：
  1.305±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C，需保存在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 5-formylpyrrole-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-formylpyrrole-2-carboxylate
CAS number: 1197-13-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7NO3
Molecular weight: 153.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  甲基 5-醛基-1H-吡咯-2-甲酸酯 在 potassium permanganate 、 草酰氯 、 sodium methylate 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 5-(diaminomethylidenecarbamoyl)-1H-pyrrole-2-carbonyl chloride
  参考文献：
  名称：

  在水性溶剂中2-（胍基碘羰基）吡咯受体与羧酸盐的结合：通过额外的氢键改善胍盐阳离子的结合性能。

  摘要：

  已经合成了一系列胍二羰基吡咯受体，其通过与多个氢键结合的离子对结合羧酸盐。使用NMR滴定研究在40％水/ DMSO（v / v）中研究了它们与各种羧酸盐的结合性能。最好的受体具有大约为K的缔合常数，大约等于10（3）mol（-1），因此比简单的乙酰胍鎓阳离子大约30倍。通过受体结构的系统变化，可以得出个体结合相互作用的能量贡献的半定量估计。这些数据表明，各种氢键对于结合而言并非同等重要，但它们在整个络合过程中的能量贡献却显着不同。此外，该受体可以被制成手性的，并且在对映体氨基酸羧酸盐结合后显示出选择性。分子模型用于获得各种受体羧酸盐配合物的结构信息，并作为解释观察到的结合常数差异的基础。

  DOI：

  10.1002/(sici)1521-3765(20000218)6:4<709::aid-chem709>3.0.co;2-6
• 作为产物：
  描述：

  吡咯-2-羧酸 在 POCl₂ 作用下， 生成 甲基 5-醛基-1H-吡咯-2-甲酸酯
  参考文献：
  名称：

  Development of 5-(aminomethyl)pyrrole-2-carboxylic acid as a constrained surrogate of Gly-ΔAla and its application in peptidomimetic studies

  摘要：

  A new peptidomimetic scaffold based on 5-(aminomethyl)pyrrole-2-carboxylic acid (1) is developed for the first time and used as a conformationally constrained surrogate of the Gly-DeltaAla dipeptide isostere (2) to prepare peptides 3 and 4. (C) 2002 Published by Elsevier Science.

  DOI：

  10.1016/s0040-4039(02)00342-8

文献信息

• [EN] SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY<br/>[FR] DÉRIVÉS D'OXINDOLE SPIRO-SUBSTITUÉS AYANT UNE ACTIVITÉ SUR AMPK
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014202580A1

  公开（公告）日：2014-12-24

  The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及具有有价值的药理特性的式(I)化合物，特别是AMPK激活剂，因此在治疗某些可以通过激活该受体预防或治疗的疾病方面具有用处。这些化合物适用于治疗和预防可以受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• Carbene‐Catalyzed Enantioselective Aromatic N‐Nucleophilic Addition of Heteroarenes to Ketones
  作者：Yonggui Liu、Guoyong Luo、Xing Yang、Shichun Jiang、Wei Xue、Yonggui Robin Chi、Zhichao Jin

  DOI：10.1002/anie.201912160

  日期：2020.1.2

  and optical purities. Our reaction involves the formation of an unprecedented aza-fulvene-type acylazolium intermediate. A broad range of N-heteroaromatic aldehydes and electron-deficient ketone substrates works effectively in this transformation. Several of the chiral N,O-acetal products afforded through this protocol exhibit excellent antibacterial activities against Ralstonia solanacearum (Rs) and

  杂芳基醛的芳族氮原子被卡宾催化剂活化以与酮亲电子试剂反应。以良好至优异的产率和光学纯度提供多功能的环状N，O-乙缩醛产物。我们的反应涉及空前的氮杂富烯型酰基唑鎓中间体的形成。各种各样的N-杂芳族醛和缺电子的酮底物可以有效地实现这种转化。通过该协议提供的几种手性N，O-乙缩醛产品表现出优异的抗青枯菌（Rsstonia solanacearum）的抗菌活性，在开发用于植物保护的新型农业化学品中具有重要的价值。
• [EN] OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY<br/>[FR] OXINDOLES SUBSTITUÉS PAR OLÉFINE AYANT UNE ACTIVITÉ SUR AMPK
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014202528A1

  公开（公告）日：2014-12-24

  The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及具有有价值的药理特性的式(I)化合物，特别是AMPK激活剂，因此在治疗某些可以通过激活该受体预防或治疗的疾病方面具有用处。这些化合物适用于治疗和预防可以受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• NOVEL ROCK INHIBITORS
  申请人：Leysen Dirk

  公开号：US20140057942A1

  公开（公告）日：2014-02-27

  The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, —NH—, or a direct bond; Y is —NH— or a direct bond; n is an integer from 0 to 4; m is an integer from 0 to 4; Cy represents a bivalent radical consisting of a satured (poly)cycle, including fused, bi-, spiro or bridged carbocycles and heterocycles; in particular selected from the group consisting of: Formula (II), Ar is selected from the group comprising: Formula (III), R 2 is hydrogen or methyl; R 8 is hydrogen, methyl, halogen, or alkynyl; R 1 is an aryl or heteroaryl more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

  本发明涉及新型激酶抑制剂，其化学式为(I)，其中X是氧、—NH—或直接键；Y是—NH—或直接键；n是从0到4的整数；m是从0到4的整数；Cy代表由饱和（多）环组成的二价基团，包括融合的、双的、螺环或桥接的碳环和杂环；特别是从以下组中选择：化学式（II），Ar是从包括化学式（III）的组中选择；R2是氢或甲基；R8是氢、甲基、卤素或炔基；R1是芳基或杂芳基，更具体地是ROCK抑制剂，包含此类抑制剂的组合物，特别是药品，以及此类抑制剂在治疗和预防疾病中的用途。特别是，本发明涉及新型ROCK抑制剂，包含此类抑制剂的组合物，特别是药品，以及此类抑制剂在治疗和预防疾病中的用途。此外，本发明还涉及治疗方法以及使用所述化合物在制造药品中的应用，用于治疗包括性功能障碍、炎症性疾病、眼科疾病和呼吸系统疾病等多种治疗适应症。
• [EN] CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA<br/>[FR] HÉTÉROCYCLES À 5 CHAÎNONS CONTENANT DE L'AZOTE SUBSTITUÉS PAR CARBOXAMIDE OU SULFONAMIDE EN TANT QUE MODULATEURS POUR LE RÉCEPTEUR NUCLÉAIRE ORPHELIN ROR GAMMA
  申请人：PHENEX PHARMACEUTICALS AG

  公开号：WO2014023367A1

  公开（公告）日：2014-02-13

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了针对孤儿核受体RORγ的调节剂，以及通过向需要的人类或哺乳动物施用这些新型的RORγ调节剂来治疗RORγ介导的疾病的方法。具体而言，本发明提供含有羧酰胺的环状化合物，其化学式从公式(1)到公式(5)，以及它们的对映异构体、非对映异构体、互变异构体、N-氧化物、溶剂化物和药用可接受的盐。

表征谱图